Procter & Gamble
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Procter & Gamble
Demand for OTC pain relievers and cough/cold products jumped prior to October-December and remained high during quarter due to consumer concern not only about flu but also RSV and additional COVID-19 mutation. US and Canadian firms marketing OTC drugs and supplements also will be offering additional signals on planned spinoffs of consumer health businesses.
Mersana signs its third ADC partnership with big pharmas for the year with Merck agreement. Lilly expands its RNA editing partnership with ProQR, which now has the potential to earn an additional $2.5bn. Novartis continues its divestment efforts in deals with Harrow, Erasca.
Abbott Laboratories and Johnson & Johnson joined Medtronic in putting a clear distance between themselves and other global medtechs in the Top 10 by revenues for 2021. Post-COVID-19 procedure growth, and, for Abbott, a strong rebound in non-COVID diagnostic demand, were key drivers.
Unisom Sleeptab with 25 mg doxylamine is first OTC sleep remedy adding warning not to drive a vehicle or operate machinery and five others FDA requested in “changes being effected” letter. Agency’s ongoing review found “labeling deficiencies” with doxylamine and diphenhydramine.
- OTC, Consumer
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.